Acknowledgements The authors are grateful for the support received from the Austrian Science Fund (FWF, P 29379-B28), the Tyrolean Science Fund (TWF, 0404/1812), the Austrian Society of Gastroenterology and Hepatology (GGH) and the European Crohns and Colitis Organisation (ECCO) (to T.E.A.)
The inhibition of SIRP- CD47-SHP-1 axis by using CD47 antagonist, under clinical evaluation, leads to SnCs elimination and maintain the homeostasis of tissues
DSIP has a plasma half-life of only a few minutes due to rapid degradation by blood peptidasesyet behavioral effects in sleep normalization and HPA axis modulation persist for days to weeks after a single administration
Potential Imbalances : Excessive levels of certain nutrients could pose health concerns, highlighting the importance of professional supervision
Animal studies at effective doses showed no overt toxicity, but this cannot be extrapolated to human safety